ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P49-25 Requirement to Submit Appeals Via Availity Essentials
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 01, 2025
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 271 - 280 လၢ 3562 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P48-25 Specialty Utilization Management (UM) Programs for Minnesota Health Care Program (MHCP) Products
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 01, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P47-25 Prime Therapeutics Management (UM) Program: Medical Drug Updates
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 01, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P46-25 New Medical and Behavioral Health Policy Management Updates, Effective October 6, 2025
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 01, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP60-25 MHCP Pharmacy Benefit Exclusion for Emrelis™, Jubbonti®, Pyzchiva®, Ryzneuta®, Wyost® and Zevaskyn™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 09, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP59-25 Commercial Pharmacy Benefit Exclusion for Jubbonti®, Pyzchiva®, Ryzneuta®, Wyost® and Zevaskyn™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 09, 2025